Longer-term results for Janssen Pharmaceutical Cos. and Legend Biotech Corp.’s ciltacabtagene autoleucel (cilta-cel) show that multiple myeloma patients treated with the B-cell maturation antigen (BCMA)-targeting chimeric antigen receptor T-cell (CAR-T) therapy maintained responses over time. But while the overall response and complete response rates reported on 5 December at the virtual American Society of Hematology (ASH) annual meeting are higher than those observed with idecabtagene vicleucel (ide-cel) from Bristol Myers Squibb Company and bluebird bio, longer-term data for ide-cel show lower incidences of cytokine release syndrome (CRS) and severe neurotoxicity.
The BMS/bluebird asset also has the benefit of time, since a biologic license application (BLA) for ide-cel already is under review at the US Food and